Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure–response relations from two phase II clinical trials

Rifapentine is a highly active antituberculosis antibiotic with treatment‐shortening potential; however, exposure–response relations and the dose needed for maximal bactericidal activity have not been established. We used pharmacokinetic/pharmacodynamic data from 657 adults with pulmonary tuberculos...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Pharmacol Ther
Päätekijät: Savic, RM, Weiner, M, MacKenzie, WR, Engle, M, Whitworth, WC, Johnson, JL, Nsubuga, P, Nahid, P, Nguyen, NV, Peloquin, CA, Dooley, KE, Dorman, SE
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2017
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5545752/
https://ncbi.nlm.nih.gov/pubmed/28124478
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.634
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia